KDM4C and hematopoietic and lymphoid system neoplasm: JMJD2C has been reported to play a crucial role in the progression of breast cancer, prostate carcinomas, osteosarcoma, and blood neoplasms, thus indicating that JMJD2C represents a promising anti-cancer target [39,40,41].